MedTrace Logo

Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors

NCT00002572 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2013-05-30

No results posted yet for this study

Summary

RATIONALE: Biological therapy uses different ways to stimulate the immune system and stop cancer cells from growing. Cytotoxic T cells combined with interleukin-2 may be an effective treatment for recurrent brain tumors.

PURPOSE: Phase I trial to study the effectiveness of cytotoxic T cells and interleukin-2 in treating adults with recurrent brain tumors.

Conditions

Interventions

BIOLOGICAL

aldesleukin

BIOLOGICAL

muromonab-CD3

BIOLOGICAL

therapeutic tumor infiltrating lymphocytes

PROCEDURE

conventional surgery

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Kevin O. Lillehei, MD · University of Colorado, Denver

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-11-30
Primary Completion
1999-12-31
Completion
1999-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002572 on ClinicalTrials.gov